Details of the Drug Reposition

General Information of This Drug (ID: DMJ9ZIY)

Drug Name
CK-2017357   DMJ9ZIY
Synonyms
Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Amyotrophic lateral sclerosis DISF7HVM 8B60.0 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Muscle fatigue DISAWLUT FB32.5 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8280).